A quiet revolution is unfolding in the pharmacies of the Global South, one that challenges the 'Subscription Body' model favoured by Western pharmaceutical giants. While firms like Eli Lilly and Novo Nordisk continue to gate-keep weight-loss therapies behind high-priced monthly paywalls, generic drugmakers in India have begun flooding the market with $15 alternatives. This is a righteous liberation of the working-class metabolism from the grip of corporate monopolies.

In India, where 80 percent of healthcare is paid for out-of-pocket, these generics are a lifeline for millions suffering from diabetes and obesity. It is a classic Distributist victory: the decentralisation of a vital resource that was once the exclusive province of the wealthy. While Western elites enjoy 'Wegovy HD' as a luxury status symbol, the biological working class is finally finding a way to reclaim their health without surrendering their financial independence to a corporate subscription.

We must view this as a lesson in stewardship. The human body is a temple, not a profit centre for multinational entities. When we allow essential medicine to be financialized, we turn our citizens into serfs of the biotech industry. The rise of these generic alternatives suggests that the market can, and should, serve the common good rather than the other way around. We should welcome a world where health is no longer a luxury reserved for the few.